The Safety And Feasibility of Pressurised Intraperitoneal Aerosol Chemotherapy (PIPAC) in the treatment of Unresectable Disseminated Peritoneal Malignancy

Some cancers spread to the lining of the abdominal cavity (called peritoneal carcinomatosis), and once this happens, standard chemotherapy given through a drip into a vein often can't reach the affected area effectively. This study is testing a specialised technique called PIPAC — Pressurised Intraperitoneal Aerosol Chemotherapy — where chemotherapy is converted into a fine mist and administered directly inside the abdomen during a keyhole surgical procedure. Because the drug is delivered exactly where the cancer is, rather than circulating through the whole body, it may be more effective and cause fewer systemic side effects. This study will assess whether PIPAC is safe, whether it shrinks or stabilises the cancer, and how it affects quality of life in patients whose cancer has stopped responding to standard treatment. You may be eligible if you are 18 or older and have peritoneal carcinomatosis from gastric, pancreatic, appendix, or colorectal cancer that has not responded to standard chemotherapy and cannot be surgically removed. People with bowel obstruction, recent cancer treatment (within four weeks), pregnancy, severe organ dysfunction, or large amounts of abdominal fluid are not eligible.